<link rel="stylesheet" href="/res/styles.39be4579664c3a48.css">
Evento

Safety and tolerability of bevacizumab in dogs: A clinical assesment

Sabella, Patricia ; Denzoin, Laura ; Clausse, María Icon; Gutierrez, Maria Verónica ; Benavente, Micaela Andrea Icon; Landivar, María Florencia ; Escuer, Grisel Elin ; Martinez, Sofía ; Alvarez, Luis Ignacio Icon

Otros responsables

Fecha

2026

Editorial

John Wiley & Sons

Revista

Título del libro

Nombre del evento

16th International Congress of the European Association for Veterinary Pharmacology and Toxicology

Fecha del evento

2026-06-28

Institución organizadora

European Association for Veterinary Pharmacology and Toxicology

ISSN

0140-7783

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Congreso

Clasificación temática

Resumen

Background: Bevacizumab (BCM) is a monoclonal antibody designed to inhibit vascular endothelial growth factor (VEGF), thereby inducing the regression of tumour vasculature. Given that human and canine VEGF share 93% homology, there is a strong molecular rationale for its therapeutic application in dogs. Hypothesis: This study aimed to establish clinical protocols for BCM in canine patients, testing the hypothesis that the drug maintains a favourable safety profile in this species. Methods: The study was conducted in three sequential phases (I, II, and III) to evaluate the safety of BCM at escalating doses of 5, 10, and 15 mg/kg, respectively. In each phase, BCM was administered via continuous intravenous infusion on days 0 (90 min), 14 (60 min), and 21 (30 min). Each experimental cohort consisted of a treatment group and a vehicle control group (n=8 per group). The potential toxicity of BCM was evaluated pre- and post-treatment through clinical inspections, complete blood counts, serum biochemistry, and urinalysis. Results: Neither BCM nor the vehicle was associated with local adverse reactions at the injection site. Systemic adverse events observed during BCM infusion were primarily consistent with Type I hypersensitivity. These reactions occurred predominantly after the second and third infusions. Affected subjects responded favourably to emergency intervention (adrenaline+dexamethasone). Premedication (15–30 min prior to infusion) with dexamethasone and diphenhydramine (Phase III), significantly reduced both the frequency and severity of infusion-related adverse events associated with BCM. Conclusion: Overall, the evaluated BCM regimen was well tolerated in healthy dogs; however, close monitoring of hepatic and renal function remains recommended pre- and post-administration.

Colecciones

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa